Hopatenord (Tablets) Instructions for Use
Marketing Authorization Holder
Zvezda Media, LLC (Russia)
Manufactured By
Severnaya Zvezda NAO (Russia)
ATC Code
N06BX (Other psychostimulants and nootropic drugs)
Active Substance
Hopantenic acid (Rec.INN registered by WHO)
Dosage Forms
| Hopatenord | Tablets 250 mg: 20, 40, 50 or 60 pcs. | |
| Tablets 500 mg: 20, 40, 50 or 60 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score on one side.
| 1 tab. | |
| Calcium hopantenate | 250 mg |
Excipients: hydroxypropyl methylcellulose (hypromellose) – 7.5 mg, magnesium carbonate hydroxide pentahydrate (basic magnesium carbonate hydrate) – 40.1 mg, talc – 9.3 mg, calcium stearate – 3.1 mg.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
20 pcs. – bottles (1) – cardboard packs.
Tablets white or almost white, round, flat-cylindrical, with a bevel and a score on one side.
| 1 tab. | |
| Calcium hopantenate | 500 mg |
Excipients: hydroxypropyl methylcellulose (hypromellose) – 15 mg, magnesium carbonate hydroxide pentahydrate (basic magnesium carbonate hydrate) – 80.2 mg, talc – 18.6 mg, calcium stearate – 6.2 mg.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (6) – cardboard packs.
20 pcs. – jars (1) – cardboard packs.
20 pcs. – bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Nootropic drug
Pharmacotherapeutic Group
Nootropic agent
Pharmacological Action
A nootropic agent with neurometabolic, neuroprotective, and neurotrophic properties. It increases the brain’s resistance to hypoxia and exposure to toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, has an anticonvulsant effect, and reduces motor excitability while regulating behavior.
It increases mental and physical performance. It helps to normalize GABA levels in chronic alcohol intoxication and subsequent ethanol withdrawal. It exhibits an analgesic effect.
Pharmacokinetics
After oral administration, it is rapidly absorbed from the gastrointestinal tract. Tmax is 1 hour. The highest concentrations are found in the liver, kidneys, stomach wall, and skin. It penetrates the blood-brain barrier. It is not metabolized.
It is excreted unchanged within 48 hours: 67.5% of the administered dose is excreted in the urine, 28.5% in the feces.
Indications
Cerebrovascular insufficiency caused by atherosclerotic changes in the cerebral vessels, senile dementia (initial forms), residual organic brain lesions in adults and the elderly, cerebral organic insufficiency in patients with schizophrenia, extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (including Huntington’s chorea, hepatocerebral dystrophy, Parkinson’s disease), residual effects of previous neuroinfections, post-vaccinal encephalitis, traumatic brain injury (as part of complex therapy); extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic), as a corrector for the side effects of antipsychotic agents (neuroleptics) and for prophylactic purposes simultaneously as “cover therapy”; epilepsy (with mental slowness in combination with anticonvulsants).
Psycho-emotional overload, decreased mental and physical performance (improving concentration and memory). Urination disorders: enuresis, daytime urinary incontinence, pollakiuria, imperative urges (adults and children from 2 years).
Children: perinatal encephalopathy, intellectual disability (delay in mental, speech, motor development, or their combination), infantile cerebral palsy, stuttering (mainly clonic form), epilepsy (as part of combination therapy with anticonvulsants, especially in polymorphic seizures and minor epileptic fits).
ICD codes
| ICD-10 code | Indication |
| E83.0 | Disorders of copper metabolism (Wilson's disease) |
| F01 | Vascular dementia |
| F03 | Unspecified dementia |
| F07 | Personality and behavioral disorders due to disease, damage or dysfunction of the brain |
| F20 | Schizophrenia |
| F21 | Schizotypal disorder |
| F22 | Chronic delusional disorders |
| F23 | Acute and transient psychotic disorders |
| F25 | Schizoaffective disorders |
| F29 | Unspecified nonorganic psychosis |
| F79 | Unspecified intellectual disabilities |
| F98.0 | Nonorganic enuresis |
| F98.5 | Stuttering [stammering] |
| G04 | Encephalitis, myelitis and encephalomyelitis |
| G09 | Sequelae of inflammatory diseases of the central nervous system |
| G10 | Huntington's chorea |
| G20 | Parkinson's disease |
| G21.0 | Malignant neuroleptic syndrome |
| G25 | Other extrapyramidal and movement disorders |
| G40 | Epilepsy |
| G80 | Cerebral palsy |
| G93.4 | Unspecified encephalopathy |
| I67.2 | Cerebral atherosclerosis |
| I69 | Sequelae of cerebrovascular diseases |
| P91 | Other disturbances of cerebral status of newborn |
| R32 | Urinary incontinence |
| R35 | Polyuria (including frequent micturition, nocturia) |
| S06 | Intracranial injury |
| T88.1 | Other complications following immunization, not elsewhere classified |
| T90 | Sequelae of injuries of head |
| Y49.3 | Phenothiazine antipsychotics and neuroleptics |
| Y49.4 | Butyrophenone and thioxanthene derivative neuroleptics |
| Y49.5 | Other antipsychotics and neuroleptics |
| Z73.0 | Burn-out |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| 1D00.Z | Infectious encephalitis, not elsewhere classified, unspecified |
| 1D02.Z | Infectious myelitis, not elsewhere classified, unspecified |
| 1D0Z | Non-viral and unspecified infections of the central nervous system, unspecified |
| 5C64.0Z | Disorders of copper metabolism, unspecified |
| 6A00.Z | Disorders of intellectual development, unspecified |
| 6A01.1 | Developmental speech fluency disorder |
| 6A20.Z | Schizophrenia, unspecified episode |
| 6A21.Z | Schizoaffective disorder, unspecified |
| 6A22 | Schizotypal disorder |
| 6A23.Z | Acute and transient psychotic disorder, unspecified |
| 6A24.Z | Delusional disorder, unspecified |
| 6A2Z | Schizophrenia or other primary psychotic disorders, unspecified |
| 6C00.Z | Enuresis, unspecified |
| 6D81 | Dementia due to cerebrovascular disease |
| 6D8Z | Dementia, unknown or unspecified cause |
| 6E68 | Secondary emotionally labile personality disorder |
| 6E6Z | Unspecified secondary mental or behavioral syndromes |
| 8A00.0Z | Parkinson's disease, unspecified |
| 8A00.2Y | Other specified secondary parkinsonism |
| 8A01.10 | Huntington's chorea |
| 8A0Y | Other specified movement disorders |
| 8A0Z | Motor impairments, unspecified |
| 8A6Z | Epilepsy or epileptic seizures, unspecified |
| 8B25.Z | Sequelae of cerebrovascular disease, unspecified |
| 8B41 | Myelitis |
| 8D2Z | Cerebral palsy, unspecified |
| 8E47 | Encephalopathy, not elsewhere classified |
| 8E4A.0 | Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord |
| 8E63 | Post-cardiopulmonary bypass encephalopathy |
| 8E7Z | Diseases of the nervous system, unspecified |
| BD55 | Asymptomatic stenosis of intracranial or extracranial artery |
| KB0Z | Neurological disorders specific to the perinatal or neonatal period, unspecified |
| LD90.1 | Early-onset parkinsonism-mental retardation |
| MF50.0 | Frequent micturition |
| MF50.1 | Pollakiuria |
| MF50.2Z | Unspecified urinary incontinence |
| MF55 | Polyuria |
| NA07.Z | Intracranial injury, unspecified |
| NA0Z | Head injury, unspecified |
| NE80.Z | Injury or harm arising from infusion, transfusion, or therapeutic injection, not elsewhere classified, unspecified |
| PL00 | Drugs, medicaments or biological substances causing injury or harm in therapeutic use |
| QD85 | Burn-out |
| QE01 | Stress, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
It is taken orally. A single dose for adults is 0.5-1 g, for children – 0.25-0.5 g; the daily dose for adults is 1.5-3 g, for children – 0.75-3 g. The course of treatment is 1-4 months, in some cases – up to 6 months. A repeated course of treatment can be carried out after 3-6 months.
For children with intellectual disability and oligophrenia – 0.5 g 4-6 times/day daily for 3 months; for delayed speech development – 0.5 g 3-4 times/day for 2-3 months.
As a corrector for neuroleptic syndrome, adults – 0.5-1 g 3 times/day, children – 0.25-0.5 g 3-4 times/day. The course of treatment is 1-3 months.
For epilepsy, children – 0.25-0.5 g 3-4 times/day, adults – 0.5-1 g 3-4 times/day, daily, for a long time (up to 6 months).
For tics, adults – 1.5-3 g/day, daily, for 1-5 months; children – 0.25-0.5 g 3-6 times/day daily for 1-4 months.
For urination disorders, adults – 0.5-1 g 2-3 times/day, daily dose – 2-3 g; for children, a single dose is 0.25-0.5 g, daily – 25-50 mg/kg. The course of treatment is 0.5-3 months.
Adverse Reactions
Allergic reactions rhinitis, conjunctivitis, skin rash.
Contraindications
Acute severe kidney diseases, first trimester of pregnancy.
Use in Pregnancy and Lactation
Use is contraindicated in the first trimester of pregnancy.
Use in Renal Impairment
The drug is contraindicated in acute severe kidney diseases.
Pediatric Use
Use is possible according to the dosing regimen.
Special Precautions
Long-term therapy with hopantenic acid in combination with other nootropic and CNS stimulating agents is not recommended.
Drug Interactions
It prolongs the action of barbiturates, enhances the effects of anticonvulsants, nootropic and CNS stimulating agents, and the action of local anesthetics (procaine).
It prevents the side effects of phenobarbital, carbamazepine, and antipsychotic agents (neuroleptics).
The effect of hopantenic acid is enhanced in combination with glycine and xydiphone.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer